Ranbaxy plans generic augmentin launch in US next month
THE country’s largest drugmaker, Ranbaxy Laboratories, has announced that the US market would soon have the generic version of GlaxoSmithKline’s blockbuster antibiotic Augmentin with the company planning its launch in January next year.

Biocon to produce enzymes for cardio surgery in India
ONCE its biologicals plant commences, Biocon India is planning to start manufacturing streptokinaze- enzymes used to break down blood clots especially in cardio vascular related surgeries in India.

Merck India to continue diagnostics biz
Though Merck KgaA plans to sell its diagnostics business to fellow German firm DiaSys, its subsidiary Merck India has informed the Bombay Stock Exchange that it will continue its diagnostic business in India.

BIFR directs IDBI to rebid for HAL
The Board for Industrial & Financial Reconstruction (BIFR) has directed the Industrial Development Bank of India (IDBI), the operating agency appointed by BIFR for the strategic sell off of the pharma PSU, to rebid for Hindustan Antibiotics Ltd (HAL).

JBCPL gets US & SA patents for 20 NCEs
J B Chemicals & Pharmaceuticals Limited (JBCPL) has announced a major breakthrough in its R&D activity with the US and South African patent offices granting patents for all the 20 New Chemical Entities (NCEs) invented by the company’s R&D team in the therapeutic category of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).